Christof Burkart

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

Helmut Oettle, Stefan Post, P. Neuhaus et al. · JAMA · 2007 · 2.4K citations

Medicine, Oncology, Surgery +13

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i>^V600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

Sebastian Stintzing, Kathrin Heinrich, David Tougeron et al. · Journal of Clinical Oncology · 2023 · 68 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.

Christof Burkart, Carsten Bokemeyer, Bodo Klump et al. · PubMed · 2007 · 54 citations

Medicine, Oncology, Pharmacology +17

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

Sebastian Stintzing, Kathrin Heinrich, David Tougeron et al. · Journal of Clinical Oncology · 2021 · 38 citations

Medicine, Oncology, Pharmacotherapy +14

Evaluation of circulating tumor <scp>DNA</scp> as a prognostic and predictive biomarker in <i>BRAF</i> <scp>V600E</scp> mutated colorectal cancer—results from the <scp>FIRE</scp> ‐4.5 study

Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel et al. · Molecular Oncology · 2024 · 10 citations · Full text

Medicine, Molecular Medicine, Oncology +17